Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis
Top Cited Papers
Open Access
- 9 June 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 74 (5) , 2452-2466
Abstract
Background and Aims: NAFLD is the most common liver disease worldwide. NASH, the progressive form of NAFLD, and advanced fibrosis are associated with poor outcomes. We searched for their noninvasive biomarkers. Approach and Results: Global RNA sequencing of liver tissue from 98 patients with biopsy‐proven NAFLD was performed. Unsupervised hierarchical clustering well distinguished NASH from nonalcoholic fatty liver (NAFL), and patients with NASH exhibited molecular abnormalities reflecting their pathological features. Transcriptomic analysis identified proteins up‐regulated in NASH and/or advanced fibrosis (stage F3‐F4), including matricellular glycoprotein thrombospondin‐2 (TSP‐2), encoded by the thrombospondin 2 (THBS2) gene. The intrahepatic THBS2 expression level showed the highest areas under the receiver operating characteristic curves (AUROCs) of 0.915 and 0.957 for diagnosing NASH and advanced fibrosis, respectively. THBS2 positively correlated with inflammation and ballooning according to NAFLD activity score, serum aspartate aminotransferase and hyaluronic acid (HA) levels, and NAFLD Fibrosis Score (NFS). THBS2 was associated with extracellular matrix and collagen biosynthesis, platelet activation, caspase‐mediated cleavage of cytoskeletal proteins, and immune cell infiltration. Serum TSP‐2 expression was measured in 213 patients with biopsy‐proven NAFLD, was significantly higher in NASH than in NAFL, and increased parallel to fibrosis stage. The AUROCs for predicting NASH and advanced fibrosis were 0.776 and 0.856, respectively, which were comparable to Fibrosis‐4 index, serum HA level, and NFS in advanced fibrosis diagnosis. Serum TSP‐2 level and platelet count were independent predictors of NASH and advanced fibrosis. Serum TSP‐2 levels could stratify patients with NAFLD according to the risk of hepatic complications, including liver cancer and decompensated cirrhotic events. Conclusions: TSP‐2 may be a useful biomarker for NASH and advanced fibrosis diagnosis in patients with NAFLD.Keywords
Funding Information
- Horizon 2020 Framework Programme (634413)
- Innovative Medicines Initiative (777377)
- Japan Agency for Medical Research and Development (JP20fk0210074)
- Ministry of Education, Culture, Sports, Science and Technology (20H03661)
This publication has 32 references indexed in Scilit:
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2015
- Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver diseaseNature Communications, 2014
- Hepatic Gene Expression Profiles Differentiate Presymptomatic Patients With Mild Versus Severe Nonalcoholic Fatty Liver DiseaseHepatology, 2013
- The ThrombospondinsCold Spring Harbor Perspectives in Biology, 2011
- Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic SteatohepatitisHepatology, 2009
- WGCNA: an R package for weighted correlation network analysisBMC Bioinformatics, 2008
- Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stageJournal of Gastroenterology, 2007
- Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver DiseaseGastroenterology, 2005
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999